Rocket Pharmaceuticals (RCKT)
(Delayed Data from NSDQ)
$21.98 USD
-0.12 (-0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $21.97 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Rocket Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 373 | 356 | 389 | 483 | 304 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 8 | 3 | 5 | 4 |
Total Current Assets | 378 | 364 | 392 | 487 | 308 |
Net Property & Equipment | 39 | 29 | 22 | 19 | 29 |
Investments & Advances | 34 | 43 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 64 | 65 | 31 | 31 | 31 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 566 | 552 | 497 | 591 | 372 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 46 | 37 | 20 | 25 | 17 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 2 | 2 | 2 | 2 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 5 | 0 |
Total Current Liabilities | 49 | 39 | 22 | 33 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 35 | 45 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 19 | 19 | 19 | 19 | 0 |
Other Non-Current Liabilities | 3 | 3 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 74 | 62 | 42 | 87 | 65 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,451 | 1,203 | 946 | 826 | 490 |
Retained Earnings | -959 | -714 | -492 | -323 | -183 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 493 | 490 | 455 | 504 | 307 |
Total Liabilities & Shareholder's Equity | 566 | 552 | 497 | 591 | 372 |
Total Common Equity | 493 | 490 | 455 | 504 | 307 |
Shares Outstanding | 90.10 | 75.60 | 64.50 | 55.20 | 50.30 |
Book Value Per Share | 5.47 | 6.48 | 7.05 | 9.12 | 6.11 |
Fiscal Year End for Rocket Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 373 | 437 | 307 | 331 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 10 | 5 | 7 |
Total Current Assets | NA | 378 | 447 | 312 | 338 |
Net Property & Equipment | NA | 39 | 37 | 33 | 31 |
Investments & Advances | NA | 34 | 0 | 0 | 29 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 64 | 64 | 65 | 65 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 566 | 599 | 462 | 515 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 46 | 31 | 31 | 29 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 2 | 2 | 2 | 2 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 49 | 33 | 34 | 31 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 19 | 19 | 19 | 19 |
Other Non-Current Liabilities | NA | 2 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 74 | 58 | 59 | 56 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 1,451 | 1,440 | 1,241 | 1,230 |
Retained Earnings | NA | -959 | -900 | -838 | -772 |
Other Equity | NA | 0 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 493 | 541 | 403 | 459 |
Total Liabilities & Shareholder's Equity | NA | 566 | 599 | 462 | 515 |
Total Common Equity | 0 | 493 | 541 | 403 | 459 |
Shares Outstanding | 90.50 | 90.10 | 80.50 | 80.40 | 80.40 |
Book Value Per Share | 0.00 | 5.47 | 6.72 | 5.01 | 5.71 |